Use of long-acting muscarinic antagonists for severe asthma: insights from clinicians in the SHARP network
Our findings show that barriers and heterogeneous approaches still limit LAMA prescription for severe asthma in Europe, potentially leading to the underuse of this treatment option. Establishing a clear role for LAMA within a precision medicine framework is crucial; this aspect is not yet firmly supported by current international recommendations.
Authors
- Emmanuelle Berret (ORCID: https://orcid.org/0000-0002-3603-4873)
- Pierpaolo Marchetti (ORCID: https://orcid.org/0000-0003-4139-925X)
- Jacob K. Sont (ORCID: https://orcid.org/0000-0002-5840-0651)
- Aruna T. Bansal (ORCID: https://orcid.org/0000-0002-7262-6534)
- Florence Schleich (ORCID: https://orcid.org/0000-0002-2678-1373)
- Stefania Principe (ORCID: https://orcid.org/0000-0001-7277-699X)
- Marco Caminati (ORCID: https://orcid.org/0000-0001-7383-1487)
- Svetlana Sergejeva
- Apostolos Bossios (ORCID: https://orcid.org/0000-0002-0494-2690)
- Alessandro Marcon (ORCID: https://orcid.org/0000-0002-2778-658X)
- Celeste Porsbjerg (ORCID: https://orcid.org/0000-0003-4825-9436)
- Luigi Martinelli (ORCID: https://orcid.org/0000-0001-6319-7646)
Institutions
- University of Verona (IT)
- Karolinska University Hospital (SE)
- University of Liège (BE)
- Leiden University Medical Center (NL)
- Bispebjerg Hospital (DK)
- European Respiratory Society (CH)
- Karolinska Institutet (SE)
- North Estonia Medical Centre (EE)
- Amgen (United Kingdom) (GB)
- Centre Hospitalier Universitaire de Liège (BE)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Respiratory Research
- Published
- 2025-11-04
- DOI
- https://doi.org/10.1186/s12931-025-03378-4
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00